Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen

Italian Survey on adjuvant treatment of non-small cell lung cancer / Banna, Gl; Di Maio, M; Follador, A; Collovà, E; Menis, J; Novello, S; Bria, E; Isa, Co-Authors; Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Barbieri, F; Barletta, E; Balzelloni, Ml; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Garetto, L; Gebbia, V; Genestreti, G; Gentile, Al; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, Mr; Verderame, F; Zanelli, F; Zanon, E. - In: LUNG CANCER. - ISSN 0169-5002. - 73:1(2011), pp. 78-88. [10.1016/j.lungcan.2010.10.020]

Italian Survey on adjuvant treatment of non-small cell lung cancer

Buti S;Tiseo M;
2011-01-01

Abstract

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen
2011
Italian Survey on adjuvant treatment of non-small cell lung cancer / Banna, Gl; Di Maio, M; Follador, A; Collovà, E; Menis, J; Novello, S; Bria, E; Isa, Co-Authors; Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Barbieri, F; Barletta, E; Balzelloni, Ml; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Garetto, L; Gebbia, V; Genestreti, G; Gentile, Al; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, Mr; Verderame, F; Zanelli, F; Zanon, E. - In: LUNG CANCER. - ISSN 0169-5002. - 73:1(2011), pp. 78-88. [10.1016/j.lungcan.2010.10.020]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906862
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact